AGY:LSE-Allergy Therapeutics (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 13.25

Change

-0.25 (-1.85)%

Market Cap

GBX 0.10B

Volume

0.01M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AGY Stock Forecast & Price:
Based on the Allergy Therapeutics stock forecasts from 0 analysts, the average analyst target price for Allergy Therapeutics is not available over the next 12 months. Allergy Therapeutics’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Allergy Therapeutics is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Allergy Therapeutics’s stock price was GBX 13.25. Allergy Therapeutics’s stock price has changed by +0.00% over the past week, -8.62% over the past month and -62.68% over the last year.

No recent analyst target price found for Allergy Therapeutics
No recent average analyst rating found for Allergy Therapeutics

About Allergy Therapeutics (AGY:LSE)

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to g ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HLN:LSE Haleon PLC

+10.50 (+3.56%)

GBX27.06B 19.43 13.03
HIK:LSE Hikma Pharmaceuticals PLC

+21.00 (+1.38%)

GBX3.38B 12.33 6.16
INDV:LSE Indivior PLC

+114.00 (+6.82%)

GBX2.35B 81.90 7.40
HCM:LSE HUTCHMED China Ltd

-15.00 (-6.64%)

GBX1.96B 17.41 -4.94
BXP:LSE Beximco Pharmaceuticals Limite..

+4.00 (+7.77%)

GBX0.54B 5.50 0.08
AMYT:LSE Amryt Pharma plc

N/A

GBX0.46B N/A 260.86
BMK:LSE Benchmark Holdings Plc

+1.00 (+2.63%)

GBX0.28B N/A 9.64
APH:LSE Alliance Pharma plc

-0.75 (-1.68%)

GBX0.25B 23.28 9.36
ANCR:LSE Animalcare Group Plc

+2.50 (+1.15%)

GBX0.13B 74.17 12.34
ZOE:LSE Zoetic International Plc

N/A

GBX0.08B N/A 64.52

ETFs Containing AGY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -58.91% 40% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.91% 40% F 8% F
Trailing 12 Months  
Capital Gain -62.14% 33% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.14% 33% F 6% F
Trailing 5 Years  
Capital Gain -53.10% 38% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.10% 38% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain 14.02% 67% D+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.02% 67% D+ 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 65.49% 33% F 14% F
Risk Adjusted Return 21.41% 53% F 63% D
Market Capitalization 0.10B 53% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 53.13 33% F 7% F
Price/Book Ratio 2.34 47% F 27% F
Price / Cash Flow Ratio -6.76 76% C 86% B
EV/EBITDA -10.23 88% B+ 86% B
Management Effectiveness  
Return on Equity -31.69% 38% F 10% F
Return on Invested Capital -28.80% 35% F 7% F
Return on Assets -9.57% 50% F 11% F
Debt to Equity Ratio 3.90% 88% B+ 85% B
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.23 33% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector